Peptides DB
Research-centric peptide and protocol reference hub
Study 41 of 41SS-31 literatureGeroScience · Observational2026

Mitochondrial dysfunction drives age-related degeneration of the thoracic aorta.

Mitochondrial dysfunction appears to drive aortic aging, and targeting it with peptides like elamipretide may have potential for future research.

Read at GeroScienceAdd to compare

Where it sits

this study against the rest of the ss-31 corpus
3
Preclinical
29
Observational · this one
0
Open-label
4
Randomised
5
Reviews

Summary and findings

This study measured the impact of the mitochondrial-targeted peptide elamipretide (SS-31) on aortic aging in C57Bl/6 J mice. Young (5-6 month) and aged (24-25 month) mice received ELAM for 8 weeks. The treatment restored complex II-linked respiration and reduced inflammatory markers in aged mice.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.2026

Abstract

The authors’ words, as GeroScience supplied them

This study investigated the role of mitochondrial function in aortic aging. As the aorta ages, it becomes stiffer and less compliant, increasing the risk of aneurysmal disease, hypertension, and diastolic dysfunction. Given the role of mitochondrial dysfunction in non-age related aortopathies and as a hallmark of aging, we investigated its contribution to the aging aorta. Both male and female young (5-6 month) and aged (24-25 month) C57Bl/6 J mice received mitochondrial-targeted peptide elamipretide (ELAM; SS-31) for 8 weeks. ELAM restored complex II-linked respiration in aged mice to values seen in young mice, while also improving relative phosphorylative flux. ELAM treatment also reduced inflammatory MMP9 expression and elastin breaks in aged mice. Bulk RNAseq analysis revealed that ELAM treatment significantly affected the aortic transcriptome in an age-dependent manner, reducing the expression of senescent and associated pro-inflammatory genes. Mitochondrial dysfunction thus drives aortic aging and is a potential therapeutic target for future study.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the SS-31 corpus

CTargeting Mitochondrial Dysfunction With Elamipretide (SS-31) Improves Skeletal Muscle Performance in a HFpEF Rat Model.Circulation. Heart failure · 2026 · +173.2% single-fiber contractile function in soleus, p<0.001AnimalCReversal of Mitochondrial Transhydrogenase Causes Oxidative Stress in Heart Failure.Cell metabolism · 2015 · Not reported in abstract.AnimalCNovel Role for Cardiolipin as a Target of Therapy to Mitigate Myocardial Injury Caused by Venoarterial Extracorporeal Membrane Oxygenation.Circulation · 2024 · Infarct size increased to 48±7% with VA-ECMO compared to 36±8% with reperfusion alone, P<0.001.AnimalCStructural and functional characterisation of the dextran utilisome from Bacteroides thetaiotaomicron.Journal of structural biology: X · 2026 · Not reported in abstract.In vitroC4-oxo-quinoline based fluorescent chemosensors for on-site detection of G-type nerve agent mimic DCP via spectroscopic and theoretical insights.Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy · 2026 · Limit of detection for DCP: 0.14 μM for 6DEQA.In vitroDEffectiveness of virtual reality-based rehabilitation on quality of life and upper extremity functions among stroke survivors: A systematic review and meta-analysis.International journal of nursing studies advances · 2026 · SMD = -0.09, 95% CI -0.30 to 0.11, p = .36; low certainty for QoL.review